Strengths and limitations
Since IP is a relatively rare disease, research in this field with a big
cohort is a big challenge. Nevertheless, our cohort appears to be
relatively large compared to the other clinical IP studies. For more
support of evidence of our results, more studies (with greater numbers)
should be performed. Furthermore, the retrospective nature of the
intervention analyses does not provide conclusive evidence for the
future. Lastly, to date there is no minimal clinically important
difference (MCID) known of the EES-Q.